Konference: 2007 XXXI. Brněnské onkologické dny a XXI. Konference pro sestry a laboranty
Kategorie: Maligní lymfomy a leukémie
Téma: Postery
Číslo abstraktu: 113 (p251)
Autoři: MUDr. Lukáš Smolej, Ph.D.; MUDr. Jaroslava Voglová; Doc.RNDr. Ctirad Andrýs, Ph.D.
Introduction: Angiogenesis is nowadays considered an
important factor in biology of various hematological malignancies
including chronic myeloid leukemia (CML). Several studies have
recently reported elevated levels of angiogenic activators such as
vascular endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF) in CML patients. However, there have been only
few data on the influence of imatinib mesylate (IM) treatment on
the levels of angiogenic cytokines in CML. Aims: To analyze
peripheral blood levels of angiogenic activators in patients with
newly diagnosed CML and during imatinib treatment.
Methods: We measured plasma concentrations of VEGF, bFGF and soluble endoglin (sCD105) using sandwich enzyme-linked immunosorbent assay (ELISA) in 16 patients with chronic-phase CML and 80 healthy blood donors; furthemore, repeated samples during the therapy with (IM) were analyzed. Results: We found a statistically significant increase in VEGF (mean ± SD [standard deviation], 491.0 ± 365.3 vs. 64.2 ± 69.5 pg/ml, 95% CI [confidence interval] of mean, 296.4-685.7 vs. 51.0-77.5 pg/ml, p<0.0001) and sCD105 (mean ± SD, 7.0 ± 1.95 vs. 4.57 ± 1.51 ng/ml, 95% CI of mean, 5.83-8.18 vs. 4.20-4.93 ng/ml, p<0.0001) but not bFGF (p=0.606) in comparison to the control group. VEGF levels significantly decreased in 7 patients who achieved hematological remission (6 complete remissions, 1 partial remission) during therapy with IM (mean ± SD, 679.6 ± 431.5 vs. 132.7 ± 63.3 pg/ml, 95% CI, 280.6-1078.6 vs. 74.1-191.3 pg/ml, p=0.015). There was no significant change in bFGF or sCD105 (p=0.938 and 0.125, respectively). Conclusions: We found significantly elevated VEGF and sCD105 levels in CML patients. In addition, successful treatment with IM resulted in significant decrease of VEGF. These data lend further support to the importance of angiogenesis in patophysiology of CML. Further studies incorporating larger number of patients are needed to confirm our findings. Supported by research project MZO 00179906 from Ministry of Health of Czech Republic.
Methods: We measured plasma concentrations of VEGF, bFGF and soluble endoglin (sCD105) using sandwich enzyme-linked immunosorbent assay (ELISA) in 16 patients with chronic-phase CML and 80 healthy blood donors; furthemore, repeated samples during the therapy with (IM) were analyzed. Results: We found a statistically significant increase in VEGF (mean ± SD [standard deviation], 491.0 ± 365.3 vs. 64.2 ± 69.5 pg/ml, 95% CI [confidence interval] of mean, 296.4-685.7 vs. 51.0-77.5 pg/ml, p<0.0001) and sCD105 (mean ± SD, 7.0 ± 1.95 vs. 4.57 ± 1.51 ng/ml, 95% CI of mean, 5.83-8.18 vs. 4.20-4.93 ng/ml, p<0.0001) but not bFGF (p=0.606) in comparison to the control group. VEGF levels significantly decreased in 7 patients who achieved hematological remission (6 complete remissions, 1 partial remission) during therapy with IM (mean ± SD, 679.6 ± 431.5 vs. 132.7 ± 63.3 pg/ml, 95% CI, 280.6-1078.6 vs. 74.1-191.3 pg/ml, p=0.015). There was no significant change in bFGF or sCD105 (p=0.938 and 0.125, respectively). Conclusions: We found significantly elevated VEGF and sCD105 levels in CML patients. In addition, successful treatment with IM resulted in significant decrease of VEGF. These data lend further support to the importance of angiogenesis in patophysiology of CML. Further studies incorporating larger number of patients are needed to confirm our findings. Supported by research project MZO 00179906 from Ministry of Health of Czech Republic.
Datum přednesení příspěvku: 23. 4. 2007
